Official US Government Icon

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure Site Icon

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

The latest information on the Coronavirus Disease 2019 (COVID-19) is available on coronavirus.gov.

United States Department of Transportation United States Department of Transportation

MRB Task 15-1: Type I Diabetes

Medical Review Board (MRB)

Task Statement 15 – 1

 

I. Task Title

Recommendations to the Agency on the disposition of comments from medical professionals and associations to the Agency’s Notice of Proposed Rulemaking (NPRM) on insulin-dependent drivers of commercial motor vehicles (CMV) with diabetes mellitus.

II. Background

Diabetes mellitus (Type I) is a disease manifested by the body’s inability to maintain normal function of insulin, a substance that controls glycemic levels in the blood.  Diabetes presents a major health challenge to the health of all Americans, particularly those who drive CMVs in interstate commerce.  Since 2006, FMCSA has maintained an exemption program for Type I diabetics, those who are insulin-dependent, that allows them to drive in interstate commerce if their diabetes is stable and they meet an experience threshold. 

In May 2015, we issued an NPRM announcing a proposal in the Federal Register to allow drivers with stable, well-controlled insulin-treated diabetes mellitus (ITDM) to be qualified to operate CMVs in interstate commerce.  This NPRM would enable individuals with ITDM to obtain a Medical Examiner's Certificate (MEC) from a ME at least annually in order to operate in interstate commerce as long as evidence is presented by the treating clinician who prescribes insulin to the driver documenting that the condition is stable and well-controlled.  The comment period closed on July 6.

III. Task

The Agency received more than 1,250 comments to the NPRM.  In an effort to have the MRB assist the Agency in furthering this rulemaking, we ask the members to review and analyze all the comments from medical professionals and associations and identify factors the Agency should consider with regard to making a decision about the next step in the diabetes rulemaking.

IV. Estimated Time to Complete Task

The MRB should provide a letter report to the Administrator outlining its recommendations in advance of its September 2015 meeting.

V.  FMCSA Technical Representatives

  • Larry Minor, Associate Administrator for Policy, FMCSA, (202) 366-5221
  • Chuck Horan, Director, Office of Carrier, Driver, and Vehicle Standards, (202) 366-5370
  • Shannon Watson, Senior Policy Advisor, FMCSA, (202) 366-5221
  • Eileen Gregory-Nolan, RN, MRB Liaison, (202) 366-4001
Last updated: Wednesday, August 12, 2015